BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 16988579)

  • 21. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
    DeAngelo DJ
    Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clofarabine (2-chloro-2'-fluoro-2'-deoxyarabinosyladenine)--biochemical aspects of anticancer activity.
    Majda K; Lubecka K; Kaufman-Szymczyk A; Fabianowska-Majewska K
    Acta Pol Pharm; 2011; 68(4):459-66. PubMed ID: 21796927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia.
    Choi J; Foss F
    Yale J Biol Med; 2006 Dec; 79(3-4):169-72. PubMed ID: 17940627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of clofarabine activity in childhood and adult acute leukemia: individual tumor response study.
    Styczynski J; Gil L; Derwich K; Wachowiak J; Balwierz W; Badowska W; Krawczuk-Rybak M; Matysiak M; Wieczorek M; Balcerska A; Sonta-Jakimczyk D; Stefaniak J; Kowalczyk J; Urasinski T; Sobol G; Komarnicki M; Wysocki M
    Anticancer Res; 2009 May; 29(5):1643-50. PubMed ID: 19443380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clofarabine for treatment of acute lymphoblastic leukaemia in adults.
    Rodríguez Vargas B; Sánchez Cuervo M; Bermejo Vicedo T
    Farm Hosp; 2011; 35(1):47-9. PubMed ID: 20673734
    [No Abstract]   [Full Text] [Related]  

  • 26. [Therapeutic effect of clofarabine in children with relapsed or refractory acute lymphoblastic leukemia].
    Suo P; Zhang LP; Wu J; Lu AD; Wang B; Zuo YX; Cheng YF; Liu GL
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jun; 15(6):444-7. PubMed ID: 23791059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup.
    Huguet F; Leguay T; Raffoux E; Rousselot P; Vey N; Pigneux A; Ifrah N; Dombret H
    Leuk Lymphoma; 2015 Apr; 56(4):847-57. PubMed ID: 24996442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia.
    O'Connor D; Sibson K; Caswell M; Connor P; Cummins M; Mitchell C; Motwani J; Taj M; Vora A; Wynn R; Kearns PR
    Br J Haematol; 2011 Aug; 154(4):482-5. PubMed ID: 21689087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clofarabine.
    Pui CH; Jeha S
    Nat Rev Drug Discov; 2005 May; Suppl():S12-3. PubMed ID: 15962525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog.
    Faderl S; Gandhi V; Keating MJ; Jeha S; Plunkett W; Kantarjian HM
    Cancer; 2005 May; 103(10):1985-95. PubMed ID: 15803490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clofarabine.
    Drugs R D; 2004; 5(4):213-7. PubMed ID: 15230627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia.
    Jeha S; Gandhi V; Chan KW; McDonald L; Ramirez I; Madden R; Rytting M; Brandt M; Keating M; Plunkett W; Kantarjian H
    Blood; 2004 Feb; 103(3):784-9. PubMed ID: 14551141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity.
    Lech-Maranda E; Korycka A; Robak T
    Mini Rev Med Chem; 2009 Jun; 9(7):805-12. PubMed ID: 19519505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clofarabine for myelodysplastic syndromes.
    Tiu RV; Traina F; Sekeres MA
    Expert Opin Investig Drugs; 2011 Jul; 20(7):1005-14. PubMed ID: 21591997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clofarabine: emerging role in leukemias.
    Sampat K; Kantarjian H; Borthakur G
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1559-64. PubMed ID: 19715446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of anti-cancer action and pharmacology of clofarabine.
    Zhenchuk A; Lotfi K; Juliusson G; Albertioni F
    Biochem Pharmacol; 2009 Dec; 78(11):1351-9. PubMed ID: 19576186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nelarabine: new drug. T-lymphoblastic leukaemia/lymphoma: more evaluation needed.
    Prescrire Int; 2009 Feb; 18(99):3-5. PubMed ID: 19382393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nelarabine-associated reversible Guillain-Barré-like syndrome or myelopathy in an adult patient with primary refractory T-lymphoblastic lymphoma.
    Lalayanni C; Baldoumi E; Papayiannopoulos S; Tziola K; Saloum R; Anagnostopoulos A
    Curr Probl Cancer; 2017; 41(2):138-143. PubMed ID: 28169005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience.
    Barba P; Sampol A; Calbacho M; Gonzalez J; Serrano J; Martínez-Sánchez P; Fernández P; García-Boyero R; Bueno J; Ribera JM
    Am J Hematol; 2012 Jun; 87(6):631-4. PubMed ID: 22431002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report.
    Gidwani P; Ramesh KH; Liu Y; Kolb EA
    Chemotherapy; 2008; 54(2):120-4. PubMed ID: 18303261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.